Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Profits are valuable, but they’re not everything. At StockStory, we help you identify the companies that have real staying power. Keeping that in mind, here is one profitable company that leverages its financial strength to beat the competition and two that may struggle to keep up.
Two Stocks to Sell:
Vail Resorts (MTN)
Trailing 12-Month GAAP Operating Margin: 15%
Founded by two Aspen, Colorado ski patrol guides, Vail Resorts (NYSE: MTN) is a mountain resort company offering luxury experiences in over 30 locations across the globe.
Why Do We Avoid MTN?
- Number of skier visits has disappointed over the past two years, indicating weak demand for its offerings
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
- Returns on capital haven’t budged, indicating management couldn’t drive additional value creation
Vail Resorts’s stock price of $146.76 implies a valuation ratio of 23.5x forward P/E. To fully understand why you should be careful with MTN, check out our full research report (it’s free).
TETRA Technologies (TTI)
Trailing 12-Month GAAP Operating Margin: 7.3%
Operating across six continents with approximately 40,000 acres of mineral-rich brine leases in Arkansas, TETRA Technologies (NYSE: TTI) provides well completion fluids and water management services to oil and gas operators.
Why Do We Pass on TTI?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 3.4% annually over the last ten years
- Smaller revenue base of $641.8 million means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
- Gross margin of 29.3% reflects its high production costs and unfavorable asset base
TETRA Technologies is trading at $8.56 per share, or 28.6x forward P/E. If you’re considering TTI for your portfolio, see our FREE research report to learn more.
One Stock to Watch:
Halozyme Therapeutics (HALO)
Trailing 12-Month GAAP Operating Margin: 35.9%
Known for transforming hours-long intravenous infusions into minutes-long subcutaneous injections, Halozyme Therapeutics (NASDAQ: HALO) develops and licenses its proprietary ENHANZE technology that enables subcutaneous delivery of injectable drugs that would otherwise require intravenous administration.
Why Do We Like HALO?
- Annual revenue growth of 38% over the last two years was superb and indicates its market share increased during this cycle
- Earnings per share grew by 24.7% annually over the last five years and trumped its peers
- Strong free cash flow margin of 47% enables it to reinvest or return capital consistently
At $90.15 per share, Halozyme Therapeutics trades at 8.9x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
